Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

Eur Heart J. 2017 Jun 7;38(22):1710-1716. doi: 10.1093/eurheartj/ehv676.
No abstract available

MeSH terms

  • Administration, Oral
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticoagulants / administration & dosage*
  • Antidotes / therapeutic use*
  • Arginine / administration & dosage
  • Arginine / analogs & derivatives
  • Consensus
  • Dabigatran / antagonists & inhibitors
  • Evidence-Based Medicine
  • Factor Xa / administration & dosage
  • Forecasting
  • Hemorrhage / chemically induced
  • Humans
  • Piperazines / administration & dosage
  • Recombinant Proteins / administration & dosage
  • Risk Factors
  • Thrombosis / drug therapy*
  • Vitamin K / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antidotes
  • PRT064445
  • Piperazines
  • Recombinant Proteins
  • Vitamin K
  • Arginine
  • idarucizumab
  • Factor Xa
  • Dabigatran
  • PER977